1	2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Obesity	_	_	NN	_	_	_	_	_
2	Before	_	_	IN	_	_	_	_	_
3	Liver	_	_	NN	_	_	_	_	_
4	Transplantation	_	_	NN	_	_	_	_	_


1	2.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	How	_	_	WRB	_	_	_	_	_
2	Should	_	_	MD	_	_	_	_	_
3	Obesity	_	_	NN	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	Defined	_	_	VBN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	Patients	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	Cirrhosis	_	_	NN	_	_	_	_	_
10	Considered	_	_	VBN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	LT	_	_	NNP	_	_	_	_	_
13	?	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	first	_	_	JJ	_	_	_	_	_
3	obstacle	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	define	_	_	VB	_	_	_	_	_
7	obesity	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	this	_	_	DT	_	_	_	_	_
10	population	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_
12	Elamparast	_	_	NNP	_	_	_	_	_
13	et	_	_	FW	_	_	_	_	_
14	al.	_	_	FW	_	_	_	_	_
15	recently	_	_	RB	_	_	_	_	_
16	summarized	_	_	VBD	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	most	_	_	RBS	_	_	_	_	_
19	commonly	_	_	RB	_	_	_	_	_
20	used	_	_	VBN	_	_	_	_	_
21	definitions	_	_	NNS	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	this	_	_	DT	_	_	_	_	_
24	group	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	patients	_	_	NNS	_	_	_	_	_
27	:	_	_	:	_	_	_	_	_


1	-	_	_	.	_	_	_	_	_


1	BMI	_	_	NNP	_	_	_	_	_
2	≥	_	_	NNS	_	_	_	_	_
3	30	_	_	CD	_	_	_	_	_
4	kg/m2	_	_	NN	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	Asian	_	_	JJ	_	_	_	_	_
7	population	_	_	NN	_	_	_	_	_
8	:	_	_	:	_	_	_	_	_
9	≥25	_	_	CD	_	_	_	_	_
10	kg/m2	_	_	CD	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	;	_	_	:	_	_	_	_	_


1	-	_	_	.	_	_	_	_	_


1	Percentage	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	fat	_	_	JJ	_	_	_	_	_
4	mass	_	_	NN	_	_	_	_	_
5	≥28	_	_	CD	_	_	_	_	_
6	%	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	men	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	≥40	_	_	CD	_	_	_	_	_
11	%	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	women	_	_	NNS	_	_	_	_	_
14	;	_	_	:	_	_	_	_	_


1	-	_	_	.	_	_	_	_	_


1	Waist	_	_	NN	_	_	_	_	_
2	circumference	_	_	NN	_	_	_	_	_
3	˃102	_	_	CD	_	_	_	_	_
4	cm	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	men	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	˃88	_	_	CD	_	_	_	_	_
9	cm	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	women	_	_	NNS	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	Asian	_	_	JJ	_	_	_	_	_
14	population	_	_	NN	_	_	_	_	_
15	:	_	_	:	_	_	_	_	_
16	A	_	_	DT	_	_	_	_	_
17	waist	_	_	NN	_	_	_	_	_
18	circumference	_	_	NN	_	_	_	_	_
19	˃90	_	_	CD	_	_	_	_	_
20	cm	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	men	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	˃80	_	_	CD	_	_	_	_	_
25	cm	_	_	NN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	women	_	_	NNS	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	;	_	_	:	_	_	_	_	_


1	-	_	_	.	_	_	_	_	_


1	Visceral	_	_	JJ	_	_	_	_	_
2	fat	_	_	NN	_	_	_	_	_
3	area	_	_	NN	_	_	_	_	_
4	≥100	_	_	CD	_	_	_	_	_
5	cm2	_	_	NN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	abdominal	_	_	JJ	_	_	_	_	_
8	computed	_	_	VBN	_	_	_	_	_
9	tomography	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	use	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	BMI	_	_	NN	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	limitations	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	decompensated	_	_	JJ	_	_	_	_	_
12	cirrhosis	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	reflected	_	_	VBN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	fact	_	_	NN	_	_	_	_	_
19	that	_	_	IN	_	_	_	_	_
20	sarcopenia	_	_	NN	_	_	_	_	_
21	outperforms	_	_	VBZ	_	_	_	_	_
22	BMI	_	_	NNP	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	predictor	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	outcomes	_	_	NNS	_	_	_	_	_
28	after	_	_	IN	_	_	_	_	_
29	LT	_	_	NNP	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	First	_	_	JJ	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	all	_	_	DT	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	high	_	_	JJ	_	_	_	_	_
7	BMI	_	_	NN	_	_	_	_	_
8	may	_	_	MD	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	due	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	fluid	_	_	NN	_	_	_	_	_
13	overload/ascites	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	not	_	_	RB	_	_	_	_	_
17	obesity	_	_	NN	_	_	_	_	_
18	per	_	_	FW	_	_	_	_	_
19	se	_	_	FW	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	exemplified	_	_	VBN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	study	_	_	NN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	which	_	_	WDT	_	_	_	_	_
28	adjusting	_	_	VBG	_	_	_	_	_
29	BMI	_	_	NN	_	_	_	_	_
30	for	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	liters	_	_	NNS	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	ascites	_	_	NNS	_	_	_	_	_
35	drained	_	_	VBN	_	_	_	_	_
36	at	_	_	IN	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	time	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	LT	_	_	NN	_	_	_	_	_
41	resulted	_	_	VBD	_	_	_	_	_
42	in	_	_	IN	_	_	_	_	_
43	moving	_	_	VBG	_	_	_	_	_
44	one-fifth	_	_	NN	_	_	_	_	_
45	of	_	_	IN	_	_	_	_	_
46	patients	_	_	NNS	_	_	_	_	_
47	from	_	_	IN	_	_	_	_	_
48	one	_	_	CD	_	_	_	_	_
49	BMI	_	_	NN	_	_	_	_	_
50	category	_	_	NN	_	_	_	_	_
51	to	_	_	TO	_	_	_	_	_
52	a	_	_	DT	_	_	_	_	_
53	lower	_	_	JJR	_	_	_	_	_
54	one	_	_	CD	_	_	_	_	_
55	.	_	_	.	_	_	_	_	_


1	Also	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	BMI	_	_	NNP	_	_	_	_	_
4	gives	_	_	VBZ	_	_	_	_	_
5	no	_	_	DT	_	_	_	_	_
6	information	_	_	NN	_	_	_	_	_
7	about	_	_	IN	_	_	_	_	_
8	body	_	_	NN	_	_	_	_	_
9	composition	_	_	NN	_	_	_	_	_
10	:	_	_	:	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	cannot	_	_	MD	_	_	_	_	_
3	tell	_	_	VB	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	difference	_	_	NN	_	_	_	_	_
6	between	_	_	IN	_	_	_	_	_
7	muscle	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	subcutaneous	_	_	JJ	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	visceral	_	_	JJ	_	_	_	_	_
13	adipose	_	_	NN	_	_	_	_	_
14	tissue	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	which	_	_	WDT	_	_	_	_	_
17	have	_	_	VBP	_	_	_	_	_
18	different	_	_	JJ	_	_	_	_	_
19	implications	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Studies	_	_	NNS	_	_	_	_	_
2	looking	_	_	VBG	_	_	_	_	_
3	at	_	_	IN	_	_	_	_	_
4	body	_	_	NN	_	_	_	_	_
5	composition	_	_	NN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	cross-sectional	_	_	JJ	_	_	_	_	_
8	imaging	_	_	NN	_	_	_	_	_
9	have	_	_	VBP	_	_	_	_	_
10	found	_	_	VBN	_	_	_	_	_
11	that	_	_	IN	_	_	_	_	_
12	sarcopenia	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	low	_	_	JJ	_	_	_	_	_
15	subcutaneous	_	_	JJ	_	_	_	_	_
16	adipose	_	_	NN	_	_	_	_	_
17	tissue	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	but	_	_	CC	_	_	_	_	_
20	not	_	_	RB	_	_	_	_	_
21	BMI	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	are	_	_	VBP	_	_	_	_	_
24	associated	_	_	VBN	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	mortality	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	male	_	_	JJ	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	female	_	_	JJ	_	_	_	_	_
31	patients	_	_	NNS	_	_	_	_	_
32	with	_	_	IN	_	_	_	_	_
33	cirrhosis	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	respectively	_	_	RB	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Excessive	_	_	JJ	_	_	_	_	_
2	visceral	_	_	JJ	_	_	_	_	_
3	fat	_	_	NN	_	_	_	_	_
4	when	_	_	WRB	_	_	_	_	_
5	associated	_	_	VBN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	sarcopenia	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	term	_	_	NN	_	_	_	_	_
11	known	_	_	VBN	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	sarcopenic	_	_	JJ	_	_	_	_	_
14	obesity	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	also	_	_	RB	_	_	_	_	_
18	associated	_	_	VBN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	increased	_	_	VBN	_	_	_	_	_
21	mortality	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	case	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	living	_	_	VBG	_	_	_	_	_
6	donor	_	_	NN	_	_	_	_	_
7	liver	_	_	NN	_	_	_	_	_
8	transplant	_	_	NN	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	LDLT	_	_	NN	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	sarcopenia	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	myosteatosis	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	visceral-to-subcutaneous-adipose-tissue	_	_	JJ	_	_	_	_	_
21	ratio	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	but	_	_	CC	_	_	_	_	_
24	not	_	_	RB	_	_	_	_	_
25	visceral	_	_	JJ	_	_	_	_	_
26	or	_	_	CC	_	_	_	_	_
27	subcutaneous	_	_	JJ	_	_	_	_	_
28	tissue	_	_	NN	_	_	_	_	_
29	on	_	_	IN	_	_	_	_	_
30	their	_	_	PRP$	_	_	_	_	_
31	own	_	_	JJ	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	have	_	_	VBP	_	_	_	_	_
34	been	_	_	VBN	_	_	_	_	_
35	associated	_	_	VBN	_	_	_	_	_
36	with	_	_	IN	_	_	_	_	_
37	mortality	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	reinforces	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	fact	_	_	NN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	more	_	_	JJR	_	_	_	_	_
7	than	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	size	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	patient	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	which	_	_	WDT	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	what	_	_	WP	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	BMI	_	_	NNP	_	_	_	_	_
19	stands	_	_	VBZ	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	it	_	_	PRP	_	_	_	_	_
23	is	_	_	VBZ	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	composition	_	_	NN	_	_	_	_	_
26	that	_	_	WDT	_	_	_	_	_
27	matters	_	_	VBZ	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	same	_	_	JJ	_	_	_	_	_
4	reasons	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	waist	_	_	NN	_	_	_	_	_
7	circumference	_	_	NN	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	not	_	_	RB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	best	_	_	JJS	_	_	_	_	_
12	method	_	_	NN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	assess	_	_	VB	_	_	_	_	_
15	obesity	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	these	_	_	DT	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Trying	_	_	VBG	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	circumvent	_	_	VB	_	_	_	_	_
4	some	_	_	DT	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	these	_	_	DT	_	_	_	_	_
7	limitations	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	European	_	_	NNP	_	_	_	_	_
11	Association	_	_	NNP	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	Study	_	_	NNP	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	Liver	_	_	NN	_	_	_	_	_
18	guidelines	_	_	NNS	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	nutrition	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	patients	_	_	NNS	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	cirrhosis	_	_	NN	_	_	_	_	_
25	recommend	_	_	VBP	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	adjust	_	_	VB	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	BMI	_	_	NN	_	_	_	_	_
30	for	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	confounding	_	_	VBG	_	_	_	_	_
33	effect	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	fluid	_	_	NN	_	_	_	_	_
36	retention	_	_	NN	_	_	_	_	_
37	(	_	_	-LRB-	_	_	_	_	_
38	i.	_	_	FW	_	_	_	_	_
39	e.	_	_	FW	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	dry-BMI	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	though	_	_	IN	_	_	_	_	_
45	there	_	_	EX	_	_	_	_	_
46	is	_	_	VBZ	_	_	_	_	_
47	no	_	_	DT	_	_	_	_	_
48	perfect	_	_	JJ	_	_	_	_	_
49	correlation	_	_	NN	_	_	_	_	_
50	between	_	_	IN	_	_	_	_	_
51	BMI	_	_	NN	_	_	_	_	_
52	and	_	_	CC	_	_	_	_	_
53	ascites	_	_	NNS	_	_	_	_	_
54	,	_	_	,	_	_	_	_	_
55	and	_	_	CC	_	_	_	_	_
56	in	_	_	IN	_	_	_	_	_
57	fact	_	_	NN	_	_	_	_	_
58	,	_	_	,	_	_	_	_	_
59	BMI	_	_	NN	_	_	_	_	_
60	corrected	_	_	VBN	_	_	_	_	_
61	for	_	_	IN	_	_	_	_	_
62	ascites	_	_	NNS	_	_	_	_	_
63	drained	_	_	VBN	_	_	_	_	_
64	at	_	_	IN	_	_	_	_	_
65	the	_	_	DT	_	_	_	_	_
66	time	_	_	NN	_	_	_	_	_
67	of	_	_	IN	_	_	_	_	_
68	LT	_	_	NNP	_	_	_	_	_
69	failed	_	_	VBD	_	_	_	_	_
70	to	_	_	TO	_	_	_	_	_
71	predict	_	_	VB	_	_	_	_	_
72	relevant	_	_	JJ	_	_	_	_	_
73	outcomes	_	_	NNS	_	_	_	_	_
74	after	_	_	IN	_	_	_	_	_
75	LT	_	_	NNP	_	_	_	_	_
76	.	_	_	.	_	_	_	_	_


1	Likewise	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	modified	_	_	VBN	_	_	_	_	_
5	BMI	_	_	NN	_	_	_	_	_
6	calculated	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	multiplying	_	_	VBG	_	_	_	_	_
9	BMI	_	_	NNP	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	kg/m2	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	serum	_	_	NN	_	_	_	_	_
15	albumin	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	g/L	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	intention	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	compensating	_	_	VBG	_	_	_	_	_
24	for	_	_	IN	_	_	_	_	_
25	volume	_	_	NN	_	_	_	_	_
26	overload	_	_	NN	_	_	_	_	_
27	was	_	_	VBD	_	_	_	_	_
28	found	_	_	VBN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	no	_	_	DT	_	_	_	_	_
31	use	_	_	NN	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	predict	_	_	VB	_	_	_	_	_
34	clinical	_	_	JJ	_	_	_	_	_
35	outcomes	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	conclusion	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	when	_	_	WRB	_	_	_	_	_
5	available	_	_	JJ	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	we	_	_	PRP	_	_	_	_	_
8	suggest	_	_	VBP	_	_	_	_	_
9	obesity	_	_	NN	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	defined	_	_	VBN	_	_	_	_	_
12	according	_	_	VBG	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	visceral	_	_	JJ	_	_	_	_	_
16	fat	_	_	NN	_	_	_	_	_
17	area	_	_	NN	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	body	_	_	NN	_	_	_	_	_
20	composition	_	_	NN	_	_	_	_	_
21	analysis	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	especially	_	_	RB	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	research	_	_	NN	_	_	_	_	_
27	setting	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	because	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	impact	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	obesity	_	_	NN	_	_	_	_	_
34	on	_	_	IN	_	_	_	_	_
35	LT	_	_	NN	_	_	_	_	_
36	may	_	_	MD	_	_	_	_	_
37	be	_	_	VB	_	_	_	_	_
38	modified	_	_	VBN	_	_	_	_	_
39	by	_	_	IN	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	coexistence	_	_	NN	_	_	_	_	_
42	of	_	_	IN	_	_	_	_	_
43	sarcopenia	_	_	NN	_	_	_	_	_
44	,	_	_	,	_	_	_	_	_
45	myosteatosis	_	_	NN	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	and/or	_	_	JJ	_	_	_	_	_
48	low	_	_	JJ	_	_	_	_	_
49	subcutaneous	_	_	JJ	_	_	_	_	_
50	adipose	_	_	NN	_	_	_	_	_
51	tissue	_	_	NN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	2.2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Should	_	_	MD	_	_	_	_	_
2	Morbidly	_	_	RB	_	_	_	_	_
3	Obese	_	_	NNP	_	_	_	_	_
4	Patients	_	_	NNS	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	Listed	_	_	VBN	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	LT	_	_	NNP	_	_	_	_	_
9	?	_	_	.	_	_	_	_	_


1	Some	_	_	DT	_	_	_	_	_
2	LT	_	_	NN	_	_	_	_	_
3	programs	_	_	NNS	_	_	_	_	_
4	consider	_	_	VBP	_	_	_	_	_
5	morbid	_	_	JJ	_	_	_	_	_
6	obesity	_	_	NN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	relative	_	_	JJ	_	_	_	_	_
9	contraindication	_	_	NN	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	LT	_	_	NNP	_	_	_	_	_
12	based	_	_	VBN	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	latest	_	_	JJS	_	_	_	_	_
16	recommendations	_	_	NNS	_	_	_	_	_
17	from	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	American	_	_	NNP	_	_	_	_	_
20	Association	_	_	NNP	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	Study	_	_	NNP	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	Liver	_	_	NNP	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	evidence	_	_	NN	_	_	_	_	_
4	evaluating	_	_	VBG	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	role	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	obesity	_	_	NN	_	_	_	_	_
9	on	_	_	IN	_	_	_	_	_
10	outcomes	_	_	NNS	_	_	_	_	_
11	after	_	_	IN	_	_	_	_	_
12	LT	_	_	NNP	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	conflicting	_	_	JJ	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	When	_	_	WRB	_	_	_	_	_
2	needed	_	_	VBN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	patients	_	_	NNS	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	severe	_	_	JJ	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	morbid	_	_	JJ	_	_	_	_	_
9	obesity	_	_	NN	_	_	_	_	_
10	do	_	_	VBP	_	_	_	_	_
11	benefit	_	_	VB	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	LT	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	meaning	_	_	VBG	_	_	_	_	_
16	they	_	_	PRP	_	_	_	_	_
17	live	_	_	VBP	_	_	_	_	_
18	longer	_	_	RBR	_	_	_	_	_
19	than	_	_	IN	_	_	_	_	_
20	they	_	_	PRP	_	_	_	_	_
21	would	_	_	MD	_	_	_	_	_
22	do	_	_	VB	_	_	_	_	_
23	without	_	_	IN	_	_	_	_	_
24	it	_	_	PRP	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	LT	_	_	NNP	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	these	_	_	DT	_	_	_	_	_
30	patients	_	_	NNS	_	_	_	_	_
31	strays	_	_	VBZ	_	_	_	_	_
32	far	_	_	RB	_	_	_	_	_
33	away	_	_	RB	_	_	_	_	_
34	from	_	_	IN	_	_	_	_	_
35	being	_	_	VBG	_	_	_	_	_
36	futile	_	_	JJ	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	with	_	_	IN	_	_	_	_	_
39	five-year	_	_	JJ	_	_	_	_	_
40	survival	_	_	NN	_	_	_	_	_
41	rates	_	_	NNS	_	_	_	_	_
42	well	_	_	RB	_	_	_	_	_
43	above	_	_	IN	_	_	_	_	_
44	50	_	_	CD	_	_	_	_	_
45	%	_	_	NN	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	Evidence	_	_	NN	_	_	_	_	_
2	so	_	_	RB	_	_	_	_	_
3	far	_	_	RB	_	_	_	_	_
4	does	_	_	VBZ	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	support	_	_	VB	_	_	_	_	_
7	using	_	_	VBG	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	strict	_	_	JJ	_	_	_	_	_
10	BMI	_	_	NN	_	_	_	_	_
11	cutoff	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	deny	_	_	VB	_	_	_	_	_
14	someone	_	_	NN	_	_	_	_	_
15	candidacy	_	_	NN	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	LT	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	however	_	_	RB	_	_	_	_	_
20	obesity	_	_	NN	_	_	_	_	_
21	is	_	_	VBZ	_	_	_	_	_
22	frequently	_	_	RB	_	_	_	_	_
23	associated	_	_	VBN	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	other	_	_	JJ	_	_	_	_	_
26	conditions	_	_	NNS	_	_	_	_	_
27	that	_	_	WDT	_	_	_	_	_
28	may	_	_	MD	_	_	_	_	_
29	be	_	_	VB	_	_	_	_	_
30	contraindications	_	_	NNS	_	_	_	_	_
31	for	_	_	IN	_	_	_	_	_
32	LT	_	_	NN	_	_	_	_	_
33	such	_	_	JJ	_	_	_	_	_
34	as	_	_	IN	_	_	_	_	_
35	cardiovascular	_	_	JJ	_	_	_	_	_
36	disease	_	_	NN	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	cancer	_	_	NN	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	renal	_	_	JJ	_	_	_	_	_
41	dysfunction	_	_	NN	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	and	_	_	CC	_	_	_	_	_
44	pulmonary	_	_	JJ	_	_	_	_	_
45	hypertension	_	_	NN	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	Also	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	obesity	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	risk	_	_	NN	_	_	_	_	_
7	factor	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	NAFLD	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	though	_	_	IN	_	_	_	_	_
13	traditionally	_	_	RB	_	_	_	_	_
14	considered	_	_	VBN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	have	_	_	VB	_	_	_	_	_
17	similar	_	_	JJ	_	_	_	_	_
18	post-LT	_	_	NN	_	_	_	_	_
19	outcomes	_	_	NNS	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	those	_	_	DT	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	other	_	_	JJ	_	_	_	_	_
24	etiologies	_	_	NNS	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	liver	_	_	NN	_	_	_	_	_
27	disease	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	may	_	_	MD	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	fact	_	_	NN	_	_	_	_	_
32	have	_	_	VB	_	_	_	_	_
33	lower	_	_	JJR	_	_	_	_	_
34	one-year	_	_	JJ	_	_	_	_	_
35	survival	_	_	NN	_	_	_	_	_
36	due	_	_	JJ	_	_	_	_	_
37	to	_	_	TO	_	_	_	_	_
38	cardiovascular	_	_	JJ	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	cerebrovascular	_	_	JJ	_	_	_	_	_
41	diseases	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	summary	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	more	_	_	JJR	_	_	_	_	_
5	than	_	_	IN	_	_	_	_	_
6	obesity	_	_	NN	_	_	_	_	_
7	itself	_	_	PRP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	it	_	_	PRP	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	sum	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	comorbidities	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	individual	_	_	JJ	_	_	_	_	_
19	patient	_	_	NN	_	_	_	_	_
20	that	_	_	WDT	_	_	_	_	_
21	determines	_	_	VBZ	_	_	_	_	_
22	LT	_	_	NN	_	_	_	_	_
23	outcomes	_	_	NNS	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	as	_	_	IN	_	_	_	_	_
26	such	_	_	JJ	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	morbid	_	_	JJ	_	_	_	_	_
29	obesity	_	_	NN	_	_	_	_	_
30	should	_	_	MD	_	_	_	_	_
31	not	_	_	RB	_	_	_	_	_
32	be	_	_	VB	_	_	_	_	_
33	considered	_	_	VBN	_	_	_	_	_
34	on	_	_	IN	_	_	_	_	_
35	its	_	_	PRP$	_	_	_	_	_
36	own	_	_	JJ	_	_	_	_	_
37	a	_	_	DT	_	_	_	_	_
38	contraindication	_	_	NN	_	_	_	_	_
39	for	_	_	IN	_	_	_	_	_
40	LT	_	_	NN	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	but	_	_	CC	_	_	_	_	_
43	in	_	_	IN	_	_	_	_	_
44	turn	_	_	NN	_	_	_	_	_
45	should	_	_	MD	_	_	_	_	_
46	trigger	_	_	VB	_	_	_	_	_
47	a	_	_	DT	_	_	_	_	_
48	rigorous	_	_	JJ	_	_	_	_	_
49	pre-LT	_	_	NN	_	_	_	_	_
50	assessment	_	_	NN	_	_	_	_	_
51	to	_	_	TO	_	_	_	_	_
52	carefully	_	_	RB	_	_	_	_	_
53	select	_	_	VB	_	_	_	_	_
54	potential	_	_	JJ	_	_	_	_	_
55	recipients	_	_	NNS	_	_	_	_	_
56	,	_	_	,	_	_	_	_	_
57	as	_	_	IN	_	_	_	_	_
58	discussed	_	_	VBN	_	_	_	_	_
59	below	_	_	RB	_	_	_	_	_
60	.	_	_	.	_	_	_	_	_

